The National Health Service (NHS) will begin funding ruxolitinib, a cream designed to restore skin colour in patients with vitiligo, marking the first licensed treatment for the condition available on the health service. The decision follows a recommendation from the National Institute for Health and Care Excellence (NICE), reversing an initial rejection of the treatment.
Ruxolitinib, manufactured by Pfizer, works by targeting the immune cells that disrupt pigmentation in the skin. Clinical trials have demonstrated the cream’s ability to increase repigmentation in affected areas, particularly on the face and other visible parts of the body. The treatment is specifically approved for non-segmental vitiligo, the most common form of the condition, affecting an estimated 80,000 patients in the UK.
NICE initially declined to endorse ruxolitinib due to concerns over its cost-effectiveness. However, a revised commercial deal with Pfizer led to the approval, making the treatment accessible to eligible patients through the NHS. The Pharmaceutical Journal reported that the updated agreement addressed the previous cost concerns, paving the way for the landmark decision.
The approval is considered a significant step forward for individuals living with vitiligo, a condition that can cause considerable psychological distress and impact quality of life. While not a cure, ruxolitinib offers the potential to significantly improve the appearance of skin affected by the condition, boosting confidence and well-being. The treatment is applied topically twice daily for a period of six months, with the potential for further courses depending on individual response.
Hospital Healthcare Europe noted that the NICE approval follows a period of advocacy from patient groups and medical professionals who highlighted the lack of effective treatment options for vitiligo. The decision underscores the importance of continued dialogue between pharmaceutical companies, healthcare bodies, and patient representatives in ensuring access to innovative therapies.
NAVLIN DAILY reported that the NICE greenlight specifically targets facial vitiligo, acknowledging the particular emotional impact of the condition when it affects visible areas. The revised commercial deal was crucial in securing access to this targeted treatment, demonstrating a willingness from both sides to find a solution.
The NHS has not yet announced a specific timeline for the rollout of ruxolitinib, but it is expected to become available to eligible patients in the coming months. Further guidance will be issued to healthcare professionals regarding patient selection and treatment protocols.
